China guideline for diagnosis and comprehensive treatment of colorectal liver metastases(version 2020)

doi:10.3877/cma.j.issn.2095-3224.2021.01.002

Abstract

Abstract:

The liver is the most common anatomical site for hematogenous metastases of colorectal cancer, and colorectal liver metastasis is one of the most difficult and challenging situations in the treatment of colorectal cancer. In order to improve the diagnosis and comprehensive treatment in China, the Guidelines have been edited and revised for several times since 2008, including the overall evaluation, personalized treatment goals and comprehensive treatments,to prevent the occurrence of liver metastases, improve the resection rate of liver metastases and survival. The revised Guideline version 2020 includes the diagnosis and follow-up, prevention,multidisciplinary team (MDT), surgery and local ablative treatment, neoadjuvant and adjuvant therapy, and comprehensive treatment, with state-of-the-art experience and findings, detailed content, and strong operability.

Key words: Colorectal neoplasms, Liver metastases, Diagnosis, Comprehensive treatment, Guideline

Chinese College of Surgeons, Section of Gastrointestinal Surgery, Branch of Surgery, Chinese Medical Association, Section of Colorectal Surgery, Branch of Surgery, Chinese Medical Association, Section of Colorectal Oncology, Oncology Branch, Chinese Medical Association, Colorectal Cancer Professional Committee, Chinese Anti⁃Cancer Association, Colorectal Cancer Professional Committee, Chinese Medical Doctor Association, Colorectal Cancer Expert Committee, Chinese Society of Clinical Oncology, Chinese Society of Colon and Rectal Surgeons, Chinese College of Surgeons, Chinese Medical Doctor Association, Metastasis Research Committee, Anorectal Branch of Chinese Medical Doctor Association, Colorectal Liver Metastases Professional Committee, China International Exchange and Promotive Association for Medical and Health Care. China guideline for diagnosis and comprehensive treatment of colorectal liver metastases(version 2020)[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2021, 10(01): 2-15.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2021.01.002

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2021/V10/I01/2

Figures/Tables 6

References 338

68	KlautkeG, FietkauR. Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review[J]. Int J Colorectal Dis, 2007, 22(5): 457-465. URL
69	MartijnseIS, DudinkRL, KustersM, et al. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen[J]. Ann Surg Oncol, 2012, 19(2): 392-401. URL
70	Sebag-MontefioreD, StephensRJ, SteeleR, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial[J]. Lancet, 2009, 373(9666): 811-820.
71	SiegelR, BurockS, WerneckeKD, et al. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society[J]. BMC Cancer, 2009, 9: 50.
72	BujkoK, WyrwiczL, RutkowskiA, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study[J]. Ann Oncol, 2016, 27(5): 834-842.
73	VermaasM, GosselinkMP, FerenschildFT, et al. Introduction of preoperative radiotherapy in the treatment of operable rectal cancer in the Southwest region of the Netherlands[J]. Eur J Surg Oncol, 2007, 33(7): 862-867.
74	CercekA, RoxburghCSD, StrombomP, et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer[J]. JAMA Oncol, 2018, 4(6): e180071.
75	PetrelliF, TrevisanF, CabidduM, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes[J]. Ann Surg, 2020, 271(3): 440-448.
76	XuJ, ZhongY, WeixinN, et al. Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery[J]. Ann Surg, 2007, 245(4): 583-590.
77	ChangW, WeiY, RenL, et al. Randomized controlled trial of intraportal chemotherapy combined with adjuvant chemotherapy (mFOLFOX6) for stage II and III colon cancer[J]. Ann Surg, 2016, 263(3): 434-439.
78	SugiharaK, OhtsuA, ShimadaY, et al. Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies[J]. Clin Colorectal Cancer, 2012, 11(2): 127-137.
79	Rodríguez-MorantaF, SalóJ, ArcusaA, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial[J]. J Clin Oncol, 2006, 24(3): 386-393.
80	AndréT, BoniC, NavarroM, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial[J]. J Clin Oncol, 2009, 27(19): 3109-3116.
81	KueblerJP, WieandHS, O'ConnellMJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07[J]. J Clin Oncol, 2007, 25(16): 2198-2204.
82	TveitKM, WiigJN, OlsenDR, et al. Combined modality treatment including intraoperative radiotherapy in locally advanced and recurrent rectal cancer[J]. Radiother Oncol, 1997, 44(3): 277-282.
83	YuTK, BhosalePR, CraneCH, et al. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 71(4): 1175-1180.
84	FennellML, DasIP, ClauserS, et al. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality[J]. J Natl Cancer Inst Monogr, 2010, 2010(40): 72-80.
85	RabinowitzB. Interdisciplinary breast cancer care: declaring and improving the standard[J]. Oncology (Williston Park), 2004, 18(10): 1263-1268; discussion 1268-1270, 1275.
86	NordlingerB, VautheyJN, PostonG, et al. The timing of chemotherapy and surgery for the treatment of colorectal liver metastases[J]. Clin Colorectal Cancer, 2010, 9(4): 212-218.
87	WrightFC, De VitoC, LangerB, et al. Multidisciplinary cancer conferences: a systematic review and development of practice standards[J]. Eur J Cancer, 2007, 43(6): 1002-1010. URL
88	JungSM, HongYS, KimTW, et al. Impact of a multidisciplinary team approach for managing advanced and recurrent colorectal cancer[J]. World J Surg, 2018, 42(7): 2227-2233.
89	DaviesAR, DeansDA, PenmanI, et al. The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer[J]. Dis Esophagus, 2006, 19(6): 496-503.
90	FleissigA, JenkinsV, CattS, et al. Multidisciplinary teams in cancer care: are they effective in the UK?[J]. Lancet Oncol, 2006, 7(11): 935-943.
91	GabelM, HiltonNE, NathansonSD. Multidisciplinary breast cancer clinics. Do they work?[J]. Cancer, 1997, 79(12): 2380-2384.
92	SchiergensTS, von EinemJ, ThomasMN, et al. Multidisciplinary treatment of colorectal liver metastases[J]. Minerva Med, 2017, 108(6): 527-546.
93	CarterS, GarsideP, BlackA. Multidisciplinary team working, clinical networks, and chambers; opportunities to work differently in the NHS[J]. Qual Saf Health Care, 2003, 12(Suppl 1): i25-28.
94	RummansTA, ClarkMM, SloanJA, et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial[J]. J Clin Oncol, 2006, 24(4): 635-642.
95	DuCZ, LiJ, CaiY, et al. Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy[J]. World J Gastroenterol, 2011, 17(15): 2013-2018.
96	MacDermidE, HootonG, MacDonaldM, et al. Improving patient survival with the colorectal cancer multi-disciplinary team[J]. Colorectal Dis, 2009, 11(3): 291-295.
97	ObiasVJ, ReynoldsHL, Jr. Multidisciplinary teams in the management of rectal cancer[J]. Clin Colon Rectal Surg, 2007, 20(3): 143-147.
98	WanisKN, Pineda-SolisK, Tun-AbrahamME, et al. Management of colorectal cancer with synchronous liver metastases: impact of multidisciplinary case conference review[J]. Hepatobiliary Surg Nutr, 2017, 6(3): 162-169.
99	LanYT, JiangJK, ChangSC, et al. Improved outcomes of colorectal cancer patients with liver metastases in the era of the multidisciplinary teams[J]. Int J Colorectal Dis, 2016, 31(2): 403-411.
1	AdamR, VinetE. Regional treatment of metastasis: surgery of colorectal liver metastases[J]. Ann Oncol, 2004, 15 (Suppl 4): iv103-106.
2	SiegelRL, MillerKD, Goding SauerA, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(3): 145-164.
3	GiannisD, SiderisG, KakosCD, et al. The role of liver transplantation for colorectal liver metastases: A systematic review and pooled analysis[J]. Transplant Rev (Orlando), 2020, 34(4): 100570.
4	TaniaiN, AkimaruK, YoshidaH, et al. Surgical treatment for better prognosis of patients with liver metastases from colorectal cancer[J]. Hepatogastroenterology, 2007, 54(78): 1805-1809.
5	QinS, LiuGJ, HuangM, et al. The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases: a review of a 4-year experience at a single center[J]. Int J Hyperthermia, 2019, 36(1): 36-43.
6	ArruM, AldrighettiL, CastoldiR, et al. Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer[J]. World J Surg, 2008, 32(1): 93-103. URL
7	VibertE, CanedoL, AdamR. Strategies to treat primary unresectable colorectal liver metastases[J]. Semin Oncol, 2005, 32(6 Suppl 8): 33-39.
8	HongYS, SongSY, LeeSI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer[J]. Ann Oncol, 2004, 15(9): 1344-1347.
9	StewartCL, WarnerS, ItoK, et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?[J]. Curr Probl Surg, 2018, 55(9): 330-379.
10	de JongMC, PulitanoC, RiberoD, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients[J]. Ann Surg, 2009, 250(3): 440-448.
11	GiulianteF, ArditoF, VelloneM, et al. Role of the surgeon as a variable in long-term survival after liver resection for colorectal metastases[J]. J Surg Oncol, 2009, 100(7): 538-545.
12	NorénA, SandströmP, GunnarsdottirK, et al. Identification of inequalities in the selection of liver surgery for colorectal liver metastases in Sweden[J]. Scand J Surg, 2018, 107(4): 294-301.
13	MargonisGA, SergentanisTN, Ntanasis-StathopoulosI, et al. Impact of surgical margin width on recurrence and overall survival following r0 hepatic resection of colorectal metastases: a systematic review and meta-analysis[J]. Ann Surg, 2018, 267(6): 1047-1055.
14	YangAD, BrouquetA, VautheyJN. Extending limits of resection for metastatic colorectal cancer: risk benefit ratio[J]. J Surg Oncol, 2010, 102(8): 996-1001.
15	SharmaS, CamciC, JabbourN. Management of hepatic metastasis from colorectal cancers: an update[J]. J Hepatobiliary Pancreat Surg, 2008, 15(6): 570-580. URL
16	TimmermanRD, BizekisCS, PassHI, et al. Local surgical, ablative, and radiation treatment of metastases[J]. CA Cancer J Clin, 2009, 59(3): 145-170.
17	LvY, FengQY, WeiY, et al. Benefits of multi-disciplinary treatment strategy on survival of patients with colorectal cancer liver metastasis[J]. Clin Transl Med, 2020, 10(3).
100	Look HongNJ, GagliardiAR, BronskillSE, et al. Multidisciplinary cancer conferences: exploring obstacles and facilitators to their implementation[J]. J Oncol Pract, 2010, 6(2): 61-68.
101	BentremDJ, DematteoRP, BlumgartLH. Surgical therapy for metastatic disease to the liver[J]. Annu Rev Med, 2005, 56: 139-156.
102	AkgülÖ, ÇetinkayaE, ErsözŞ, et al. Role of surgery in colorectal cancer liver metastases[J]. World J Gastroenterol, 2014, 20(20): 6113-6122.
103	MayoSC, PawlikTM. Current management of colorectal hepatic metastasis[J]. Expert Rev Gastroenterol Hepatol, 2009, 3(2): 131-144.
104	PostonGJ. Radiofrequency ablation of colorectal liver metastases: where are we really going?[J]. J Clin Oncol, 2005, 23(7): 1342-1344.
105	HurH, KoYT, MinBS, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases[J]. Am J Surg, 2009, 197(6): 728-736.
106	ReuterNP, WoodallCE, ScogginsCR, et al. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent?[J]. J Gastrointest Surg, 2009, 13(3): 486-491. URL
107	DexiangZ, LiR, YeW, et al. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases[J]. Ann Surg Oncol, 2012, 19(9): 2860-2868. URL
108	KhanAS, Garcia-ArozS, AnsariMA, et al. Assessment and optimization of liver volume before major hepatic resection: Current guidelines and a narrative review[J]. Int J Surg, 2018, 52: 74-81.
109	BéginA, MartelG, LapointeR, et al. Accuracy of preoperative automatic measurement of the liver volume by CT-scan combined to a 3D virtual surgical planning software (3DVSP)[J]. Surg Endosc, 2014, 28(12): 3408-3412. URL
110	YanTD, PadangR, XiaH, et al. Management of involved or close resection margins in 120 patients with colorectal liver metastases: edge cryotherapy can achieve long-term survival[J]. Am J Surg, 2006, 191(6): 735-742.
111	BlazerDG, 3rd, KishiY, MaruDM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases[J]. J Clin Oncol, 2008, 26(33): 5344-5351.
112	JaeckD. The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies[J]. Ann Surg Oncol, 2003, 10(9): 1007-1011. URL
113	PulitanòC, BodingbauerM, AldrighettiL, et al. Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection[J]. Ann Surg Oncol, 2012, 19(2): 435-442. URL
114	MargonisGA, BuettnerS, AndreatosN, et al. Prognostic factors change over time after hepatectomy for colorectal liver metastases: a multi-institutional, international analysis of 1099 patients[J]. Ann Surg, 2019, 269(6): 1129-1137.
115	JaeckD, OussoultzoglouE, RossoE. Hepatectomy for colorectal metastases in the presence of extrahepatic disease[J]. Surg Oncol Clin N Am, 2007, 16(3): 507-523, viii. URL
18	AdamR, de GramontA, FiguerasJ, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus[J]. Cancer Treat Rev, 2015, 41(9): 729-741.
19	BipatS, van LeeuwenMS, IjzermansJN, et al. Evidence-base guideline on management of colorectal liver metastases in the Netherlands[J]. Neth J Med, 2007, 65(1): 5-14.
20	MonteilJ, Le Brun-LyV, CachinF, et al. Comparison of 18FDG-PET/CT and conventional follow-up methods in colorectal cancer: A randomised prospective study[J]. Dig Liver Dis, 2020.
21	GourietF, Tissot-DupontH, CasaltaJP, et al. FDG-PET/CT Incidental Detection of Cancer in Patients Investigated for Infective Endocarditis[J]. Front Med (Lausanne), 2020, 7: 535.
22	CoenegrachtsK, De GeeterF, ter BeekL, et al. Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases[J]. Eur Radiol, 2009, 19(2): 370-379. URL
23	JonesOM, ReesM, JohnTG, et al. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection[J]. Br J Surg, 2005, 92(9): 1165-1168.
24	KoshariyaM, JagadRB, KawamotoJ, et al. An update and our experience with metastatic liver disease[J]. Hepatogastroenterology, 2007, 54(80): 2232-2239.
25	KomborozosVA, SkrekasGJ, PissiotisCA. The contribution of follow-up programs in the reduction of mortality of rectal cancer recurrences[J]. Dig Surg, 2001, 18(5): 403-408.
26	TsikitisVL, MalireddyK, GreenEA, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial[J]. J Clin Oncol, 2009, 27(22): 3671-3676.
27	PfisterDG, BensonAB, 3rd, SomerfieldMR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer[J]. N Engl J Med, 2004, 350(23): 2375-2382.
28	LockerGY, HamiltonS, HarrisJ, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer[J]. J Clin Oncol, 2006, 24(33): 5313-5327.
29	DeschCE, BensonAB, 3rd, SomerfieldMR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline[J]. J Clin Oncol, 2005, 23(33): 8512-8519.
30	RexDK, KahiCJ, LevinB, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer[J]. CA Cancer J Clin, 2006, 56(3): 160-167; quiz 185-166.
31	RexDK, KahiCJ, LevinB, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer[J]. Gastroenterology, 2006, 130(6): 1865-1871.
32	ModestDP, RicardI, HeinemannV, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group[J]. Ann Oncol, 2016, 27(9): 1746-1753.
33	TherkildsenC, BergmannTK, Henrichsen-SchnackT, et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis[J]. Acta Oncol, 2014, 53(7): 852-864. URL
116	AdamR, de HaasRJ, WichertsDA, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement?[J]. J Clin Oncol, 2008, 26(22): 3672-3680.
117	ZizzoM, GaleoneC, BragliaL, et al. Long-Term Outcomes after Surgical Resection for Synchronous or Metachronous Hepatic and Pulmonary Colorectal Cancer Metastases[J]. Digestion, 2020, 101(2): 144-155.
118	PulitanòC, BodingbauerM, AldrighettiL, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis[J]. Ann Surg Oncol, 2011, 18(5): 1380-1388. URL
119	TurriniO, ViretF, GuiramandJ, et al. Strategies for the treatment of synchronous liver metastasis[J]. Eur J Surg Oncol, 2007, 33(6): 735-740.
120	ZhaoDB, ShanY, WangCF, et al. Surgical treatment for colorectal cancer with simultaneous hepatic metastasis[J]. Chinese Journal of Oncology, 2007, 29(7): 552-554.
121	ChangGJ, KaiserAM, MillsS, et al. Practice parameters for the management of colon cancer[J]. Dis Colon Rectum, 2012, 55(8): 831-843. URL
122	CapussottiL, FerreroA, ViganòL, et al. Major liver resections synchronous with colorectal surgery[J]. Ann Surg Oncol, 2007, 14(1): 195-201. URL
123	NakajimaK, TakahashiS, SaitoN, et al. Predictive factors for anastomotic leakage after simultaneous resection of synchronous colorectal liver metastasis[J]. J Gastrointest Surg, 2012, 16(4): 821-827. URL
124	HatwellC, BretagnolF, FargesO, et al. Laparoscopic resection of colorectal cancer facilitates simultaneous surgery of synchronous liver metastases[J]. Colorectal Dis, 2013, 15(1): e21-28.
125	SchnitzbauerAA, LangSA, GoessmannH, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings[J]. Ann Surg, 2012, 255(3): 405-414.
126	RoxburghCS, RichardsCH, MougSJ, et al. Determinants of short- and long-term outcome in patients undergoing simultaneous resection of colorectal cancer and synchronous colorectal liver metastases[J]. Int J Colorectal Dis, 2012, 27(3): 363-369. URL
127	SlupskiM, WlodarczykZ, JasinskiM, et al. Outcomes of simultaneous and delayed resections of synchronous colorectal liver metastases[J]. Can J Surg, 2009, 52(6): E241-244.
128	NanjiS, MackillopWJ, WeiX, et al. Simultaneous resection of primary colorectal cancer and synchronous liver metastases: a population-based study[J]. Can J Surg, 2017, 60(2): 122-128.
129	de JongMC, van DamRM, MaasM, et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience[J]. HPB (Oxford), 2011, 13(10): 745-752.
130	de JongMC, BeckersRCJ, van WoerdenV, et al. The liver-first approach for synchronous colorectal liver metastases: more than a decade of experience in a single centre[J]. HPB (Oxford), 2018, 20(7): 631-640.
131	BrouquetA, MortensonMM, VautheyJN, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?[J]. J Am Coll Surg, 2010, 210(6): 934-941.
34	SchirripaM, CremoliniC, LoupakisF, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer[J]. Int J Cancer, 2015, 136(1): 83-90.
35	BrudvikKW, MiseY, ChungMH, et al. RAS Mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases[J]. Ann Surg Oncol, 2016, 23(8): 2635-2643.
36	PassotG, ChunYS, KopetzSE, et al. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations[J]. Eur J Surg Oncol, 2016, 42(9): 1378-1384.
37	MargonisGA, BuettnerS, AndreatosN, et al. Anatomical resections improve disease-free survival in patients with KRAS-mutated colorectal liver metastases[J]. Ann Surg, 2017, 266(4): 641-649.
38	SorichMJ, WieseMD, RowlandA, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials[J]. Ann Oncol, 2015, 26(1): 13-21.
39	MaoC, YangZY, HuXF, et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis[J]. Ann Oncol, 2012, 23(6): 1518-1525.
40	KopetzS, GrotheyA, YaegerR, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer[J]. N Engl J Med, 2019, 381(17): 1632-1643.
41	Van CutsemE, HuijbertsS, GrotheyA, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study[J]. J Clin Oncol, 2019, 37(17): 1460-1469.
42	GurenTK, ThomsenM, KureEH, et al. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study[J]. Br J Cancer, 2017, 116(10): 1271-1278.
43	SinicropeFA, ShiQ, AllegraCJ, et al. Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers : A secondary analysis of 2 randomized clinical trials[J]. JAMA Oncol, 2017, 3(4): 472-480.
44	PikoulisE, MargonisGA, AndreatosN, et al. Prognostic role of BRAF Mutations in colorectal cancer liver metastases[J]. Anticancer Res, 2016, 36(9): 4805-4811.
45	MoreiraL, BalaguerF, LindorN, et al. Identification of Lynch syndrome among patients with colorectal cancer[J]. Jama, 2012, 308(15): 1555-1565.
46	UmarA, BolandCR, TerdimanJP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability[J]. J Natl Cancer Inst, 2004, 96(4): 261-268.
47	BuchananDD, ClendenningM, RostyC, et al. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts[J]. J Gastroenterol Hepatol, 2017, 32(2): 427-438.
48	ChenS, WatsonP, ParmigianiG. Accuracy of MSI testing in predicting germline mutations of MSH2 and MLH1: a case study in Bayesian meta-analysis of diagnostic tests without a gold standard[J]. Biostatistics, 2005, 6(3): 450-464.
49	HempelmannJA, LockwoodCM, KonnickEQ, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing[J]. J Immunother Cancer, 2018, 6(1): 29.
132	WaisbergJ, IvankovicsIG. Liver-first approach of colorectal cancer with synchronous hepatic metastases: A reverse strategy[J]. World J Hepatol, 2015, 7(11): 1444-1449.
133	AbbottDE, CantorSB, HuCY, et al. Optimizing clinical and economic outcomes of surgical therapy for patients with colorectal cancer and synchronous liver metastases[J]. J Am Coll Surg, 2012, 215(2): 262-270.
134	KellyME, SpolveratoG, LêGN, et al. Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies[J]. J Surg Oncol, 2015, 111(3): 341-351.
135	PelosiE, DeandreisD. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer[J]. Eur J Surg Oncol, 2007, 33(1): 1-6.
136	TomlinsonJS, JarnaginWR, DeMatteoRP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure[J]. J Clin Oncol, 2007, 25(29): 4575-4580.
137	ShoupM, GonenM, D'AngelicaM, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection[J]. J Gastrointest Surg, 2003, 7(3): 325-330. URL
138	SarpelU, BonaviaAS, GrucelaA, et al. Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis?[J]. Ann Surg Oncol, 2009, 16(2): 379-384. URL
139	HammondJS, GuhaIN, BeckinghamIJ, et al. Prediction, prevention and management of postresection liver failure[J]. Br J Surg, 2011, 98(9): 1188-1200.
140	PawlikTM, ScogginsCR, ZorziD, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases[J]. Ann Surg, 2005, 241(5): 715-722, discussion 722-714.
141	AyezN, LalmahomedZS, EggermontAM, et al. Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2012, 19(5): 1618-1627. URL
142	PandanaboyanaS, WhiteA, PathakS, et al. Impact of margin status and neoadjuvant chemotherapy on survival, recurrence after liver resection for colorectal liver metastasis[J]. Ann Surg Oncol, 2015, 22(1): 173-179.
143	KokudoN, MikiY, SugaiS, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection[J]. Arch Surg, 2002, 137(7): 833-840.
144	AdamR, MillerR, PitomboM, et al. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases[J]. Surg Oncol Clin N Am, 2007, 16(3): 525-536, viii. URL
145	HasselgrenK, SandströmP, BjörnssonB. Role of associating liver partition and portal vein ligation for staged hepatectomy in colorectal liver metastases: a review[J]. World J Gastroenterol, 2015, 21(15): 4491-4498.
146	BjörnssonB, SparrelidE, RøsokB, et al. Associating liver partition and portal vein ligation for staged hepatectomy in patients with colorectal liver metastases--Intermediate oncological results[J]. Eur J Surg Oncol, 2016, 42(4): 531-537.
147	AbbasiA, Rahnemai-AzarAA, MerathK, et al. Role of associating liver partition and portal vein ligation in staged hepatectomy (ALPPS)-strategy for colorectal liver metastases[J]. Transl Gastroenterol Hepatol, 2018, 3: 66.
50	StellooE, JansenAML, OsseEM, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer[J]. Ann Oncol, 2017, 28(1): 96-102.
51	MarshS, HoskinsJM. Irinotecan pharmacogenomics[J]. Pharmacogenomics, 2010, 11(7): 1003-1010.
52	BarbarinoJM, HaidarCE, KleinTE, et al. PharmGKB summary: very important pharmacogene information for UGT1A1[J]. Pharmacogenet Genomics, 2014, 24(3): 177-183. URL
53	HoskinsJM, GoldbergRM, QuP, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters[J]. J Natl Cancer Inst, 2007, 99(17): 1290-1295.
54	GulerI, AskanG, KlostergaardJ, et al. Precision medicine for metastatic colorectal cancer: an evolving era[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(10): 919-931.
55	AllgäuerM, BudcziesJ, ChristopoulosP, et al. Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians[J]. Transl Lung Cancer Res, 2018, 7(6): 703-715.
56	GongJ, Chehrazi-RaffleA, ReddiS, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations[J]. J Immunother Cancer, 2018, 6(1): 8.
57	CoccoE, ScaltritiM, DrilonA. NTRK fusion-positive cancers and TRK inhibitor therapy[J]. Nat Rev Clin Oncol, 2018, 15(12): 731-747.
58	ArtaleS, Sartore-BianchiA, VeroneseSM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer[J]. J Clin Oncol, 2008, 26(25): 4217-4219.
59	Etienne-GrimaldiMC, FormentoJL, FrancoualM, et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy[J]. Clin Cancer Res, 2008, 14(15): 4830-4835.
60	KnijnN, MekenkampLJ, KlompM, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients[J]. Br J Cancer, 2011, 104(6): 1020-1026.
61	OkunoK. Surgical treatment for digestive cancer. Current issues-colon cancer[J]. Dig Surg, 2007, 24(2): 108-114.
62	BorschitzT, WachtlinD, MöhlerM, et al. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer[J]. Ann Surg Oncol, 2008, 15(3): 712-720. URL
63	ReadTE, AndujarJE, CaushajPF, et al. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status[J]. Dis Colon Rectum, 2004, 47(6): 825-831. URL
64	ChauI, ChanS, CunninghamD. Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives[J]. Clin Colorectal Cancer, 2003, 3(1): 19-33.
65	PeetersKC, MarijnenCA, NagtegaalID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma[J]. Ann Surg, 2007, 246(5): 693-701.
66	van GijnW, MarijnenCA, NagtegaalID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial[J]. Lancet Oncol, 2011, 12(6): 575-582. URL
67	KenneckeH, LimH, WoodsR, et al. Outcomes of unselected patients with pathologic T3N0 rectal cancer[J]. Radiother Oncol, 2012, 105(2): 214-219. URL
148	BertensKA, HawelJ, LungK, et al. ALPPS: challenging the concept of unresectability--a systematic review[J]. Int J Surg, 2015, 13: 280-287.
149	SpampinatoMG, MandaláL, QuartaG, et al. One-stage, totally laparoscopic major hepatectomy and colectomy for colorectal neoplasm with synchronous liver metastasis: safety, feasibility and short-term outcome[J]. Surgery, 2013, 153(6): 861-865.
150	RattiF, SchaddeE, MasettiM, et al. Strategies to increase the resectability of patients with colorectal liver metastases: a multi-center case-match analysis of ALPPS and conventional two-stage hepatectomy[J]. Ann Surg Oncol, 2015, 22(6): 1933-1942.
151	FaberW, SeehoferD, NeuhausP, et al. Repeated liver resection for recurrent hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2011, 26(7): 1189-1194.
152	AdamR, HotiE, BredtLC. Evolution of neoadjuvant therapy for extended hepatic metastases--have we reached our (non-resectable) limit?[J]. J Surg Oncol, 2010, 102(8): 922-931.
153	KanzakiR, HigashiyamaM, OdaK, et al. Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma[J]. Am J Surg, 2011, 202(4): 419-426. URL
154	EliasD, BenizriE, PocardM, et al. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer[J]. Eur J Surg Oncol, 2006, 32(6): 632-636.
155	CarpizoDR, D'AngelicaM. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease[J]. Ann Surg Oncol, 2009, 16(9): 2411-2421. URL
156	ClearyJM, TanabeKT, LauwersGY, et al. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver[J]. Oncologist, 2009, 14(11): 1095-1105.
157	TanakaK, AdamR, ShimadaH, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver[J]. Br J Surg, 2003, 90(8): 963-969.
158	LeonardGD, BrennerB, KemenyNE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma[J]. J Clin Oncol, 2005, 23(9): 2038-2048.
159	AdamsRB, HallerDG, RohMS. Improving resectability of hepatic colorectal metastases: expert consensus statement by Abdalla et al[J]. Ann Surg Oncol, 2006, 13(10): 1281-1283. URL
160	BenoistS, BrouquetA, PennaC, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?[J]. J Clin Oncol, 2006, 24(24): 3939-3945.
161	ChiappaA, BertaniE, MakuuchiM, et al. Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases[J]. Hepatogastroenterology, 2009, 56(91-92): 829-834.
162	FujisakiS, TakashinaM, SuzukiS, et al. Does complete response of liver metastases from colorectal cancer after chemotherapy mean cure?[J]. Gan To Kagaku Ryoho, 2013, 40(12): 1662-1664.
163	GruenbergerB, ScheithauerW, PunzengruberR, et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases[J]. BMC Cancer, 2008, 8: 120.
164	FolprechtG, GrotheyA, AlbertsS, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates[J]. Ann Oncol, 2005, 16(8): 1311-1319.
165	MenthaG, MajnoP, TerrazS, et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour[J]. Eur J Surg Oncol, 2007, 33 (Suppl 2): S76-83.
166	NordlingerB, SorbyeH, GlimeliusB, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial[J]. Lancet, 2008, 371(9617): 1007-1016.
167	AloiaT, SebaghM, PlasseM, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases[J]. J Clin Oncol, 2006, 24(31): 4983-4990.
168	KarouiM, PennaC, Amin-HashemM, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases[J]. Ann Surg, 2006, 243(1): 1-7.
169	KataokaK, KanazawaA, NakajimaA, et al. Feasibility and potential benefit of preoperative chemotherapy for colorectal liver metastasis (CLM): a single-centered retrospective study[J]. Surg Today, 2013, 43(10): 1154-1161. URL
170	MalikHZ, FaridS, Al-MuktharA, et al. A critical appraisal of the role of neoadjuvant chemotherapy for colorectal liver metastases: a case-controlled study[J]. Ann Surg Oncol, 2007, 14(12): 3519-3526. URL
171	StrakaM, SkrovinaM, SoumarovaR, et al. Up front hepatectomy for metastatic rectal carcinoma - reversed, liver first approach. Early experience with 15 patients[J]. Neoplasma, 2014, 61(4): 447-452. URL
172	WelshFK, TilneyHS, TekkisPP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing[J]. Br J Cancer, 2007, 96(7): 1037-1042.
173	FernandezFG, RitterJ, GoodwinJW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases[J]. J Am Coll Surg, 2005, 200(6): 845-853.
174	PawlikTM, OlinoK, GleisnerAL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome[J]. J Gastrointest Surg, 2007, 11(7): 860-868. URL
175	VautheyJN, PawlikTM, RiberoD, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases[J]. J Clin Oncol, 2006, 24(13): 2065-2072.
176	GomezD, MalikHZ, BonneyGK, et al. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis[J]. Br J Surg, 2007, 94(11): 1395-1402.
177	NakanoH, OussoultzoglouE, RossoE, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy[J]. Ann Surg, 2008, 247(1): 118-124.
178	AdamR, WichertsDA, de HaasRJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?[J]. J Clin Oncol, 2008, 26(10): 1635-1641.
179	HorganPG. Surgical management of disappearing colorectal liver metastases (Br J Surg 2013; 100: 1414-1420)[J]. Br J Surg, 2013, 100(11): 1420.
180	van VledderMG, de JongMC, PawlikTM, et al. Disappearing colorectal liver metastases after chemotherapy: should we be concerned?[J]. J Gastrointest Surg, 2010, 14(11): 1691-1700. URL
181	AdamR, DelvartV, PascalG, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival[J]. Ann Surg, 2004, 240(4): 644-657; discussion 657-648.
182	BenoistS, NordlingerB. Neoadjuvant treatment before resection of liver metastases[J]. Eur J Surg Oncol, 2007, 33 (Suppl 2): S35-41.
183	PoultsidesGA, ServaisEL, SaltzLB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment[J]. J Clin Oncol, 2009, 27(20): 3379-3384.
184	ReddySK, BarbasAS, ClaryBM. Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management?[J]. Ann Surg Oncol, 2009, 16(9): 2395-2410. URL
185	CoskunU, BuyukberberS, YamanE, et al. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients[J]. Neoplasma, 2008, 55(1): 65-70.
186	GruenbergerB, TamandlD, SchuellerJ, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(11): 1830-1835.
187	MehtaNN, RavikumarR, ColdhamCA, et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases[J]. Eur J Surg Oncol, 2008, 34(7): 782-786.
188	ParkinE, O'ReillyDA, AdamR, et al. The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy[J]. HPB (Oxford), 2013, 15(6): 463-472.
189	ClancyTE, DixonE, PerlisR, et al. Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials[J]. J Gastrointest Surg, 2005, 9(2): 198-206. URL
190	KemenyN, EidA, StockmanJ, et al. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma[J]. J Surg Oncol, 2005, 91(2): 97-101.
191	KemenyN, JarnaginW, PatyP, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer[J]. J Clin Oncol, 2005, 23(22): 4888-4896.
192	AndreT, BoniC, NavarroM, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial[J]. J Clin Oncol, 2009, 27(19): 3109-3116.
193	KishiY, ZorziD, ContrerasCM, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases[J]. Ann Surg Oncol, 2010, 17(11): 2870-2876. URL
194	BenoistS, NordlingerB. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases[J]. Ann Surg Oncol, 2009, 16(9): 2385-2390. URL
195	ChotiMA. Chemotherapy-associated hepatotoxicity: do we need to be concerned?[J]. Ann Surg Oncol, 2009, 16(9): 2391-2394. URL
196	SamantasE, DervenisC, RigatosSK. Adjuvant chemotherapy for colon cancer: evidence on improvement in survival[J]. Dig Dis, 2007, 25(1): 67-75.
197	AdamR, BhanguiP, PostonG, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?[J]. Ann Surg, 2010, 252(5): 774-787.
198	SchwarzRE, BerlinJD, LenzHJ, et al. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement[J]. HPB (Oxford), 2013, 15(2): 106-115.
199	VadeyarHJ. Current therapeutic options for colorectal liver metastases[J]. Indian J Gastroenterol, 2007, 26(1): 26-29.
200	De GreefK, RolfoC, RussoA, et al. Multisciplinary management of patients with liver metastasis from colorectal cancer[J]. World J Gastroenterol, 2016, 22(32): 7215-7225.
201	GoereD, BenhaimL, BonnetS, et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy[J]. Ann Surg, 2013, 257(1): 114-120.
202	HouseMG, KemenyNE, GonenM, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer[J]. Ann Surg, 2011, 254(6): 851-856.
203	KemenyNE, JarnaginWR, CapanuM, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer[J]. J Clin Oncol, 2011, 29(7): 884-889. URL
204	AbdallaEK. Commentary: Radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology[J]. Am J Surg, 2009, 197(6): 737-739.
205	FolprechtG, GruenbergerT, BechsteinWO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial[J]. Lancet Oncol, 2010, 11(1): 38-47. URL
206	AdamR. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases[J]. Ann Oncol, 2003, 14 (Suppl 2): ii13-16.
207	GoldbergRM, SargentDJ, MortonRF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial[J]. J Clin Oncol, 2006, 24(21): 3347-3353.
208	CalsL, RixeO, FrancoisE, et al. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients[J]. Ann Oncol, 2004, 15(7): 1018-1024.
209	FalconeA, RicciS, BrunettiI, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest[J]. J Clin Oncol, 2007, 25(13): 1670-1676.
210	TournigandC, AndreT, AchilleE, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study[J]. J Clin Oncol, 2004, 22(2): 229-237.
211	HochsterHS, HartLL, RamanathanRK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study[J]. J Clin Oncol, 2008, 26(21): 3523-3529.
212	GoereD, DeshaiesI, de BaereT, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases[J]. Ann Surg, 2010, 251(4): 686-691.
213	MahnkenAH, PereiraPL, de BaereT. Interventional oncologic approaches to liver metastases[J]. Radiology, 2013, 266(2): 407-430. URL
214	NishiofukuH, TanakaT, AramakiT, et al. Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis[J]. Clin Colorectal Cancer, 2010, 9(5): 305-310.
215	KabbinavarFF, SchulzJ, McCleodM, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial[J]. J Clin Oncol, 2005, 23(16): 3697-3705.
216	SaltzLB, ClarkeS, Diaz-RubioE, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study[J]. J Clin Oncol, 2008, 26(12): 2013-2019.
217	Van CutsemE, KöhneCH, HitreE, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(14): 1408-1417.
218	FrakerDL, SoulenM. Regional therapy of hepatic metastases[J]. Hematol Oncol Clin North Am, 2002, 16(4): 947-967.
219	CirocchiR, TrastulliS, AbrahaI, et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer[J]. Cochrane Database Syst Rev, 2012, (8): CD008997.
220	NitzkorskiJR, FarmaJM, WatsonJC, et al. Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection[J]. Ann Surg Oncol, 2012, 19(2): 379-383. URL
221	ColucciG, GebbiaV, PaolettiG, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale[J]. J Clin Oncol, 2005, 23(22): 4866-4875.
222	NorenA, ErikssonHG, OlssonLI. Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study[J]. Eur J Cancer, 2016, 53: 105-114.
223	Rubbia-BrandtL, GiostraE, BrezaultC, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery[J]. Ann Oncol, 2007, 18(2): 299-304.
224	YuQ, ZhangL, FanS, et al. The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases[J]. J Cancer Res Ther, 2016, 12(Supplement): C205-C211.
225	GhiringhelliF, VincentJ, BengrineL, et al. Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study[J]. J Cancer Res Clin Oncol, 2019, 145(9): 2357-2363.
226	KindlerHL, ShulmanKL. Metastatic colorectal cancer[J]. Curr Treat Options Oncol, 2001, 2(6): 459-471.
227	LiuY, WuW, HongW, et al. Raltitrexed-based chemotherapy for advanced colorectal cancer[J]. Clin Res Hepatol Gastroenterol, 2014, 38(2): 219-225.
228	ZelekL, BugatR, CherquiD, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial)[J]. Ann Oncol, 2003, 14(10): 1537-1542.
229	FahyBN, D'AngelicaM, DeMatteoRP, et al. Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention[J]. Ann Surg Oncol, 2009, 16(2): 361-370. URL
230	PiessevauxH, BuyseM, SchlichtingM, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab[J]. J Clin Oncol, 2013, 31(30): 3764-3775. URL
231	SuzukiC, BlomqvistL, SundinA, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy[J]. Ann Oncol, 2012, 23(4): 948-954.
232	YeLC, WeiY, ZhuDX, et al. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab[J]. J Gastroenterol Hepatol, 2015, 30(4): 674-679.
233	AlbertsSR, HorvathWL, SternfeldWC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study[J]. J Clin Oncol, 2005, 23(36): 9243-9249.
234	GiacchettiS, ItzhakiM, GruiaG, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery[J]. Ann Oncol, 1999, 10(6): 663-669.
235	PernotS, ArtruP, MithieuxF, et al. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial[J]. Clin Res Hepatol Gastroenterol, 2015, 39(6): e73-77.
236	TangW, RenL, LiuT, et al. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: The BECOME randomized controlled trial[J]. J Clin Oncol, 2020, 38(27): 3175-3184.
237	YeLC, LiuTS, RenL, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases[J]. J Clin Oncol, 2013, 31(16): 1931-1938. URL
238	KarapetisCS, JonkerD, DaneshmandM, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17[J]. Clin Cancer Res, 2014, 20(3): 744-753.
239	GarufiC, TorselloA, TumoloS, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial[J]. Br J Cancer, 2010, 103(10): 1542-1547.
240	SouglakosJ, AndroulakisN, SyrigosK, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)[J]. Br J Cancer, 2006, 94(6): 798-805.
241	CremoliniC, LoupakisF, AntoniottiC, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study[J]. Lancet Oncol, 2015, 16(13): 1306-1315.
242	SteinA, AtanackovicD, HildebrandtB, et al. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer[J]. Br J Cancer, 2015, 113(6): 872-877.
243	TomaselloG, PetrelliF, GhidiniM, et al. FOLFOXIRI Plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: A systematic review and pooled analysis[J]. JAMA Oncol, 2017, 3(7): e170278.
244	EsinE, YalcinS. Maintenance strategy in metastatic colorectal cancer: A systematic review[J]. Cancer Treat Rev, 2016, 42: 82-90.
245	GoeyKKH, EliasSG, van TinterenH, et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study[J]. Ann Oncol, 2017, 28(9): 2128-2134.
246	Hegewisch-BeckerS, GraevenU, LerchenmullerCA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial[J]. Lancet Oncol, 2015, 16(13): 1355-1369.
247	SimkensLH, van TinterenH, MayA, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group[J]. Lancet, 2015, 385(9980): 1843-1852.
248	SteinA, SchwenkeC, FolprechtG, et al. Effect of application and intensity of bevacizumab-based maintenance after induction chemotherapy with bevacizumab for metastatic colorectal cancer: A meta-analysis[J]. Clin Colorectal Cancer, 2016, 15(2): e29-39.
249	SonbolMB, MountjoyLJ, FirwanaB, et al. The role of maintenance strategies in metastatic colorectal cancer: A systematic review and network meta-analysis of randomized clinical trials[J]. JAMA Oncol, 2020, 6(3): e194489.
250	AparicioT, GhiringhelliF, BoigeV, et al. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9)[J]. J Clin Oncol, 2018, 36(7): 674-681.
251	XuRH, MuroK, MoritaS, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2018, 19(5): 660-671.
252	DucreuxM, MalkaD, MendiboureJ, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2011, 12(11): 1032-1044. URL
253	KoopmanM, AntoniniNF, DoumaJ, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial[J]. Lancet, 2007, 370(9582): 135-142.
254	SeymourMT, MaughanTS, LedermannJA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial[J]. Lancet, 2007, 370(9582): 143-152.
255	GrotheyA, Van CutsemE, SobreroA, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2013, 381(9863): 303-312. URL
256	LiJ, QinS, XuRH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial[J]. JAMA, 2018, 319(24): 2486-2496.
257	MayerRJ, Van CutsemE, FalconeA, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer[J]. N Engl J Med, 2015, 372(20): 1909-1919.
258	ShitaraK, DoiT, DvorkinM, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2018, 19(11): 1437-1448.
259	BennounaJ, BorgC, DelordJP, et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study[J]. Clin Colorectal Cancer, 2012, 11(1): 38-44.
260	IwamotoS, HazamaS, KatoT, et al. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study[J]. Anticancer Res, 2014, 34(4): 1967-1973. URL
261	HurwitzH, FehrenbacherL, NovotnyW, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 350(23): 2335-2342.
262	LeDT, UramJN, WangH, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.
263	MarabelleA, LeDT, AsciertoPA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1): 1-10.
264	LeDT, DurhamJN, SmithKN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349): 409-413.
265	YaghoubiN, SoltaniA, GhazviniK, et al. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer[J]. Biomed Pharmacother, 2019, 110: 312-318.
266	JinZ, SinicropeFA. Advances in the therapy of BRAF(V600E) metastatic colorectal cancer[J]. Expert Rev Anticancer Ther, 2019, 19(9): 823-829.
267	PrahalladA, SunC, HuangS, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR[J]. Nature, 2012, 483(7387): 100-103. URL
268	Meric-BernstamF, HurwitzH, RaghavKPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study[J]. Lancet Oncol, 2019, 20(4): 518-530.
269	Sartore-BianchiA, TrusolinoL, MartinoC, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(6): 738-746.
270	ChanDL, AlzahraniNA, MorrisDL, et al. Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases[J]. Surg Oncol, 2015, 24(3): 162-171.
271	D'AngelicaMI, Correa-GallegoC, PatyPB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes[J]. Ann Surg, 2015, 261(2): 353-360.
272	McAuliffeJC, QadanM, D'AngelicaMI. Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer[J]. J Gastrointest Oncol, 2015, 6(6): 699-708.
273	LevyJ, ZuckermanJ, GarfinkleR, et al. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis[J]. HPB (Oxford), 2018, 20(10): 905-915.
274	MinochaJ, SalemR, LewandowskiRJ. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions[J]. Clin Liver Dis, 2014, 18(4): 877-890. URL
275	AmmoriJB, KemenyNE, FongY, et al. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution[J]. Ann Surg Oncol, 2013, 20(9): 2901-2907. URL
276	MocellinS, PasqualiS, NittiD. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer[J]. Cochrane Database Syst Rev, 2009, (3): CD007823.
277	FelibertiEC, WagmanLD. Radiofrequency ablation of liver metastases from colorectal carcinoma[J]. Cancer Control, 2006, 13(1): 48-51.
278	HammillCW, BillingsleyKG, CasseraMA, et al. Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases[J]. Ann Surg Oncol, 2011, 18(7): 1947-1954. URL
279	LivraghiT, SolbiatiL, MeloniMF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study[J]. Radiology, 2003, 226(2): 441-451.
280	BerberE, TsinbergM, TelliogluG, et al. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis[J]. J Gastrointest Surg, 2008, 12(11): 1967-1972. URL
281	BrouquetA, AndreouA, VautheyJN. The management of solitary colorectal liver metastases[J]. Surgeon, 2011, 9(5): 265-272.
282	KnudsenAR, KannerupAS, MortensenFV, et al. Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy[J]. Acta Radiol, 2009, 50(7): 716-721.
283	SipersteinAE, BerberE, BallemN, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience[J]. Ann Surg, 2007, 246(4): 559-565; discussion 565-557.
284	RhimH, LimHK, KimYS, et al. Radiofrequency ablation of hepatic tumors: lessons learned from 3000 procedures[J]. J Gastroenterol Hepatol, 2008, 23(10): 1492-1500.
285	FacciorussoA, Di MasoM, MuscatielloN. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis[J]. Int J Hyperthermia, 2016, 32(3): 339-344.
286	XuZ, XieH, ZhouL, et al. The combination strategy of transarterial chemoembolization and radiofrequency ablation or microwave ablation against hepatocellular carcinoma[J]. Anal Cell Pathol (Amst), 2019, 2019: 8619096.
287	ZhangX, ChenB, HuS, et al. Microwave ablation with cooled-tip electrode for liver cancer: an analysis of 160 cases[J]. Hepatogastroenterology, 2008, 55(88): 2184-2187.
288	GrundmannRT, HermanekP, MerkelS, et al. Diagnosis and treatment of colorectal liver metastases - workflow[J]. Zentralbl Chir, 2008, 133(3): 267-284.
289	ShonoY, TabuseK, TsujiT, et al. Microwave coagulation therapy for unresectable colorectal metastatic liver tumor[J]. Gan To Kagaku Ryoho, 2002, 29(6): 856-859.
290	ChenYY, PereraDS, YanTD, et al. Applying Fong's CRS liver score in patients with colorectal liver metastases treated by cryotherapy[J]. Asian J Surg, 2006, 29(4): 238-241. URL
291	SeifertJK, JungingerT. Prognostic factors for cryotherapy of colorectal liver metastases[J]. Eur J Surg Oncol, 2004, 30(1): 34-40.
292	SeifertJK, JungingerT. Cryotherapy for liver tumors: current status, perspectives, clinical results, and review of literature[J]. Technol Cancer Res Treat, 2004, 3(2): 151-163.
293	GignouxBM, DucerfC, MabrutJY, et al. Cryosurgery of primary and metastatic cancers of the liver[J]. Ann Chir, 2001, 126(10): 950-959.
294	Austin-SeymourMM, ChenGT, CastroJR, et al. Dose volume histogram analysis of liver radiation tolerance[J]. Int J Radiat Oncol Biol Phys, 1986, 12(1): 31-35.
295	EbleMJ, GademannG, WannenmacherM. The value of radiotherapy for liver metastases[J]. Strahlenther Onkol, 1993, 169(8): 459-468.
296	YeoSG, KimDY, KimTH, et al. Whole-liver radiotherapy for end-stage colorectal cancer patients with massive liver metastases and advanced hepatic dysfunction[J]. Radiat Oncol, 2010, 5: 97.
297	MohiuddinM, ChenE, AhmadN. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer[J]. J Clin Oncol, 1996, 14(3): 722-728.
298	RusthovenKE, KavanaghBD, CardenesH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases[J]. J Clin Oncol, 2009, 27(10): 1572-1578.
299	CollettiniF, SchnapauffD, PoellingerA, et al. Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates[J]. Rofo, 2012, 184(4): 316-323. URL
300	ComitoT, CozziL, ClericiE, et al. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach[J]. BMC Cancer, 2014, 14: 619.
301	TselisN, FerentinosK, KolotasC, et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies[J]. J Thorac Oncol, 2011, 6(3): 545-552. URL
302	GoodmanKA, WiegnerEA, MaturenKE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies[J]. Int J Radiat Oncol Biol Phys, 2010, 78(2): 486-493.
303	KatzAW, Carey-SampsonM, MuhsAG, et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases[J]. Int J Radiat Oncol Biol Phys, 2007, 67(3): 793-798.
304	SchefterTE, KavanaghBD, TimmermanRD, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases[J]. Int J Radiat Oncol Biol Phys, 2005, 62(5): 1371-1378.
305	WolpinBM, MayerRJ. Systemic treatment of colorectal cancer[J]. Gastroenterology, 2008, 134(5): 1296-1310.
306	GrotheyA, SugrueMM, PurdieDM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)[J]. J Clin Oncol, 2008, 26(33): 5326-5334.
307	WelchS, SpithoffK, RumbleRB, et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review[J]. Ann Oncol, 2010, 21(6): 1152-1162.
308	TolJ, KoopmanM, CatsA, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(6): 563-572.
309	HechtJR, MitchellE, ChidiacT, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer[J]. J Clin Oncol, 2009, 27(5): 672-680.
310	SpigelDR, GrecoFA, WaterhouseD, et al. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer[J]. Clin Adv Hematol Oncol, 2010, 8(7): 480-485, 498.
311	SatoY, MatsusakaS, SuenagaM, et al. Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients[J]. Onco Targets Ther, 2015, 8: 3329-3336.
312	BokemeyerC, BondarenkoI, MakhsonA, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2009, 27(5): 663-671.
313	WongR, CunninghamD, BarbachanoY, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection[J]. Ann Oncol, 2011, 22(9): 2042-2048.
314	RaoulJL, Van LaethemJL, PeetersM, et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study[J]. BMC Cancer, 2009, 9: 112.
315	Van CutsemE, KöhneCH, LángI, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status[J]. J Clin Oncol, 2011, 29(15): 2011-2019. URL
316	PietrantonioF, CremoliniC, PetrelliF, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2015, 96(1): 156-166.
317	De RoockW, PiessevauxH, De SchutterJ, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab[J]. Ann Oncol, 2008, 19(3): 508-515.
318	KarapetisCS, Khambata-FordS, JonkerDJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J]. N Engl J Med, 2008, 359(17): 1757-1765.
319	AmadoRG, WolfM, PeetersM, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(10): 1626-1634.
320	RothAD, TejparS, DelorenziM, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial[J]. J Clin Oncol, 2010, 28(3): 466-474.
321	PriceTJ, HardinghamJE, LeeCK, et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer[J]. J Clin Oncol, 2011, 29(19): 2675-2682. URL
322	SaridakiZ, Papadatos-PastosD, TzardiM, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome[J]. Br J Cancer, 2010, 102(12): 1762-1768.
323	MaughanTS, AdamsRA, SmithCG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial[J]. Lancet, 2011, 377(9783): 2103-2114. URL
324	DouillardJY, SienaS, CassidyJ, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study[J]. J Clin Oncol, 2010, 28(31): 4697-4705.
325	McCormackL, PetrowskyH, JochumW, et al. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study[J]. Ann Surg, 2007, 245(6): 923-930.
326	Van CutsemE, RiveraF, BerryS, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study[J]. Ann Oncol, 2009, 20(11): 1842-1847.
327	LópezR, SalgadoM, ReboredoM, et al. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer[J]. Br J Cancer, 2010, 103(10): 1536-1541.
328	ChaudhuryP, HassanainM, BouganimN, et al. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis[J]. HPB (Oxford), 2010, 12(1): 37-42.
329	CartwrightTH, YimYM, YuE, et al. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology[J]. Clin Colorectal Cancer, 2012, 11(4): 238-246.
330	HamamotoY, YamaguchiT, NishinaT, et al. A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study)[J]. Oncologist, 2014, 19(11): 1131-1132. URL
331	MasiG, SalvatoreL, BoniL, et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial[J]. Ann Oncol, 2015, 26(4): 724-730.
332	BennounaJ, PhelipJM, AndréT, et al. Observational cohort study of patients with metastatic colorectal cancer initiating chemotherapy in combination with bevacizumab (CONCERT)[J]. Clin Colorectal Cancer, 2017, 16(2): 129-140.e124.
333	YinC, MaG, RongY, et al. The efficacy of bevacizumab in different line chemotherapy for chinese patients with metastatic colorectal cancer[J]. J Cancer, 2016, 7(13): 1901-1906.
334	D'AngelicaM, KornpratP, GonenM, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study[J]. Ann Surg Oncol, 2007, 14(2): 759-765. URL
335	ReddySK, MorseMA, HurwitzHI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases[J]. J Am Coll Surg, 2008, 206(1): 96-106.
336	StarlingerP, AlidzanovicL, SchauerD, et al. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation[J]. Br J Cancer, 2012, 107(6): 961-966.
337	ShitaraK, YamanakaT, DendaT, et al. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients[J]. Ann Oncol, 2019, 30(2): 259-265.
338	LiJ, QinS, XuR, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2015, 16(6): 619-629.

[1]	Shuihua Yang, Guidan He, Guican Qin, Mengfeng Liang, Yanhe Luo, Xueqin Li, Juansong Tang. Echocardioimagedata characteristics of fetal isolated total anomalous pulmonary venous connection and application of high definition flow imaging and spatio-temporal image correlation [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(10): 1061-1067.
[2]	Heng Lyu, Licong Dong, Haiqin Xie, Zhuofei Zhao, Li Liu, Desheng Sun. CT-ultrasound comparison for evaluating missed diagnosis of focal liver lesions by ultrasound: a single-center cross-sectional quality control survey [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(07): 712-716.
[3]	The Joint Surgery Branch of the Chinese Orthopedic Association, Guangdong’s Medical Association of Osteoporosis And Bone Mineral Research, Foshan Shunde 3rd Peoele’s Hospital. Clinical intervention guideline for using of anti-osteoporosis drugs in postoperative fragile hip fractures in China (2023 Edition) [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 751-764.
[4]	Peijie Li, Yongjie Qiao, Haoqiang Zhang, Jiankang Zeng, Fei Tan, Jiahuan Li, Jing Wang, Shenghu Zhou. Progress in diagnosis and treatment of periprosthetic infection with negative bacterial culture [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 827-833.
[5]	Yi He, Dongsheng Yu. Advances in diagnosis and treatment of dislocation injury of young permanent teeth [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(06): 400-406.
[6]	Xu Tang, Bing Han, Wei Liu, Ruxing Chen. Analysis of risk factors for metachronous liver metastases after radical colorectal cancer surgery and construction of a predictive model [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 16-20.
[7]	Shengjun Zhang, Ajing Zhao, Shoubo Li, Xianghong Hao, Minli Liu. An experimental study on the promotion of colorectal cancer invasion and migration by high glucose through HGF/c-met pathway [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 21-24.
[8]	Xu Peng, Yongfu Shao, Duo Li, Rui Zhou, Zhenming Xing. Diagnosis and surgical treatment of hepatocolon flexure [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 108-110.
[9]	Dingwei Xu, Jiangyun Ma, Xincheng Li, Jie Huang. Alagille syndrome misdiagnosed as congenital biliary atresia: a case report and literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 681-687.
[10]	Wenkai Ni, Chong Qi, Xiaodan Xu, Xiecheng Zhou, Qingzhang Yin, Yuankun Cai. Analysis of influencing factors of prolonged postoperative ileus in patients with colorectal cancer after operation [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 484-489.
[11]	Xiaoyu Fan, Sizheng Sun, Yimin E, Chunzhao Yu. Different surgical options for obstructive left colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 500-504.
[12]	Bing Lan, Huaiming Wang, Hui Wang, Bo Ma. Research progress on locally advanced colon cancer with bladder invasion [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 505-511.
[13]	Hongjie Yang, Zhichun Zhang, Yi Sun. Study progress in the diagnosis of lymph node metastasis of rectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 512-518.
[14]	Lili Zhao, Kuixiang Wang, Xiaochong Zhang, Zhiyuan Li. Diagnostic value of ESR to C-Reactive protein ratio in diagnosis of periprosthetic joint Infection [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2023, 09(06): 351-355.
[15]	Tian Li, Hong Xu, Heliang Liu. Progress in research of pneumoconiosis [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 900-905.

Please choose a citation manager

Content to export